Floatz logo

Bifidobacterium

Movement Disorders

Beijing Friendship HospitalPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Movement Disorders cohort.

Asset / SponsorPhaseRating
LEVODOPA
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BBB
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2BB
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4BB
BACILLUS LICHENIFORMIS
Beijing Friendship Hospital
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB

View all 21 →

Same molecule, other indications

Bifidobacterium is also rated in:

ProbioticDormant
BB
Indicative ·
65 / 100
View asset →
Rapid Eye Movement Sleep Behavior DisorderDormant
BB
Indicative ·
65 / 100
View asset →
Gut MicrobiomesDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →